JCJérôme Couturier

Jérôme Couturier

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jérôme Couturier has a total of 73 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 October 2014
      • Vol. 101  (10) , 906-7

    [Homage to Alain Bernheim].

    by Philippe Dessen, Christian-Jacques Larsen, Alexander Valent, Jérôme Couturier

  • PTP4A3, a Signal Molecule Deregulated in Uveal Melanoma Metastasis

    by Cécile Laurent, Jérôme Couturier, Xavier Sastre-Garau, Laurence Desjardins, Emmanuel Barillot, Sophie Piperno-Neumann, Simon Saule

  • Open Access

    A genomic and transcriptomic approach for a differential diagnosis between primary and secondary ovarian carcinomas in patients with a previous history of breast cancer

    by Jean-Philippe Meyniel, Paul H Cottu, Charles Decraene, Marc-Henri Stern, Jérôme Couturier, Ingrid Lebigot, André Nicolas, Nina Weber, Virginie Fourchotte, Séverine Alran, et al.

    The distinction between primary and secondary ovarian tumors may be challenging for pathologists. The purpose of the present work was to develop genomic and transcriptomic tools to further refine the pathological diagnosis of ovarian tumors after a previous history of breast cancer. Sixteen paired breast-ovary tumors from patients with a former diagnosis of breast cancer were collected. The genomic profiles of paired tumors were analyzed using the Affymetrix GeneChip® Mapping 50 K Xba Array or Genome-Wide Human SNP Array 6.0 (for one pair), and the data were normalized with ITALICS (ITerative and Alternative normaLIzation and Copy number calling for affymetrix Snp arrays) algorithm or Partek Genomic Suite, respectively. The transcriptome of paired samples was analyzed using Affymetrix GeneChip® Human Genome U133 Plus 2.0 Arrays, and the data were normalized with gc-Robust Multi-array Average (gcRMA) algorithm. A hierarchical clustering of these samples was performed, combined with a dataset of well-identified primary and secondary ovarian tumors. In 12 of the 16 paired tumors analyzed, the comparison of genomic profiles confirmed the pathological diagnosis of primary ovarian tumor (n = 5) or metastasis of breast cancer (n = 7). Among four cases with uncertain pathological diagnosis, genomic profiles were clearly distinct between the ovarian and breast tumors in two pairs, thus indicating primary ovarian carcinomas, and showed common patterns in the two others, indicating metastases from breast cancer. In all pairs, the result of the transcriptomic analysis was concordant with that of the genomic analysis. In patients with ovarian carcinoma and a previous history of breast cancer, SNP array analysis can be used to distinguish primary and secondary ovarian tumors. Transcriptomic analysis may be used when primary breast tissue specimen is not available.


  • Diagnostic de l’amplification du gène HER2 dans les cancers du sein

    by J. Couturier, A. Vincent-Salomon, M.-C. Mathieu, A. Valent, A. Bernheim


    • 1 March 2007
      • Vol. 94  (3) , 297-306

    [Reflexion on innovation diffusion factors: the case of Herceptin].

    by Catherine Buron, Marianne Doz, Anne Vincent Salomon, Jérôme Couturier, Philippe Beuzeboc, Alain Livartowski

    New innovating cancer therapies are becoming available on the market. Because medical innovations put a serious financial burden on healthcare system, it is important to understand their diffusion. To analyze this process of diffusion, the molecule trastuzumab (Herceptin) provided by Roche Laboratories was chosen. Because Herceptin is commercialized since 1999 few data are available for this analysis. The objective of this study is to identify factors and brakes associated with the diffusion of the innovation Herceptin. By identifying these factors and brakes, one can notice that Herceptin is the perfect case to illustrate a successful diffusion. All factors mentioned in E. M. Rogers theory are verified with Herceptin: benefit, simplicity, triability, observability and compatibility. The tolerance is excellent and side effects minimized except for cardiac toxicity for patients previously treated with anthracyclines. The weakness concerning financing has been overcome since France changed the payment system to a prospective payment based on the hospital activity. The only problem left is that the fluorescence in situ hybridisation (FISH) test is still not reimbursed by the social security.

    • 1 December 2003
      • Vol. 23  (6) , 617-22

    [HER2 gene amplification assay: is CISH an alternative to FISH?].

    by Yves Denoux, Laurent Arnould, Maryse Fiche, B Lannes, Jérôme Couturier, Anne Vincent-Salomon, Frédérique Penault-Llorca, M Antoine, A Balaton, M C Baranzelli, et al.

    The HER2 proto-oncogene encodes a transmembrane protein, which is considered to function as a growth factor receptor. Overexpression of this protein found by immunohistochemistry in about 20% of infiltrating breast carcinomas, has a predictive value of response to treatment by trastuzumab, an anti-HER2 humanized monoclonal antibody. Search for HER2 gene amplification is necessary to adapt the immunohistochemical technique quality and also in the cases of delicate analysis or weak overexpression. It is usually carried out by Fluorescence In Situ Hybridization (FISH). A more recent hybridization technique, named CISH because of its chromogenic revelation is an alternative method, which gives highly correlated results with FISH. We present details of this technique, which may be more familiar for the pathologists than FISH, because reading analysis is similar to that of immunohistochemical staining.


    • 1 June 2002
      • Vol. 89  (6) , 588-92

    [From the cytogenetics to the cytogenomics of thyroid tumors].

    by Bernard Perissel, Alain Bernheim, Jérôme Couturier, Geneviève Fouilhoux, Philippe Vago

    Benign and malignant thyroid tumors constitute a wide range of neoplasias showing recurrent chromosome abnormalities. Cytogenetic studies of thyroid hyperplasias and follicular adenomas revealed hyperdiplo d karyotypes with a characteristic sequence of trisomies (7, 5, 12, 14, 16, 17, 20 and 22) starting with trisomy 7. Comparative genomic hybridization (CGH) findings on thyroid oncocytic tumors showed similar chromosomal gains with no difference observed between adenomas and carcinomas. Follicular thyroid carcinomas exhibit losses of 3p25-pter predominantly or of 22,13 and 1p segments. Formation of fusion genes PAX8 - PPARgamma1 caused by a t(2;3)(q13;p25) has been observed in several cases of follicular carcinomas only. Loss of chromosome 22 has been found most frequently associated with widely invasive follicular carcinomas. Activation of the RET protooncogene through chromosome rearrangements involving subband 10q11.2 represent the most common and specific genetic alteration in papillary thyroid carcinoma. Several chimeric genes resulting in the fusion of the tyrosine kinase domain of RET with the 5' sequences of different genes have been described. Germline mutations in RET are associated with medullary thyroid carcinoma in multiple endocrine neoplasia type 2 (MEN2). Cytogenetics of thyroid tumors, using conventional and molecular methods (FISH, CGH) demonstrated that particular chromosome aberrations may be related to the clinical behavior of these tumors and may provide informations for their diagnosis or prognosis.

  • Strong Correlation between Results of Fluorescent In Situ Hybridization and Immunohistochemistry for the Assessment of the ERBB2 (HER-2/neu) Gene Status in Breast Carcinoma

    by Jérôme Couturier, Anne Vincent-Salomon, André Nicolas, Philippe Beuzeboc, Emmanuelle Mouret, Brigitte Zafrani, Xavier Sastre-Garau


  • Detection of chromosome imbalances in retinoblastoma by parallel karyotype and CGH analyses

    by Aline Mairal, Evelyne Pinglier, Elisabeth Gilbert, Martine Peter, Pierre Validire, Laurence Desjardins, Alain Aurias, François Doz, Jérôme Couturier